Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) is projected to post its results before the market opens on Monday, March 9th. Analysts expect Alzamend Neuro to post earnings of ($0.53) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings data on Tuesday, December 9th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.53. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Stock Performance

ALZN opened at $2.01 on Monday. The stock has a fifty day moving average of $2.07 and a 200-day moving average of $2.24. The company has a market capitalization of $7.64 million, a P/E ratio of -0.61 and a beta of -0.25. Alzamend Neuro has a fifty-two week low of $1.58 and a fifty-two week high of $10.17.

Institutional Trading of Alzamend Neuro

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC raised its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,506 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned approximately 0.72% of Alzamend Neuro worth $50,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on ALZN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Alzamend Neuro in a report on Monday, December 29th. Ascendiant Capital Markets dropped their price target on shares of Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.